Objective To study the changes of negative symptoms in PCP-induced schizophrenia rat model.Methods Thirty newborn female SD rats randomly divided into control group,PCP-week 6 group and PCP-week 10 group( n=10 in each group).Perinatal rat treated with PCP ( 10 mg/kg) on postnatal days 7,9 and 11(10 mg/kg,ip),and sucorse intalce test(SIT),forced swimming test(FST) and resident-intruder test(RIT) were used to test the emotional and negative symptoms.Results In the SIT,there was no difference between control and PCP groups (con:(28.24 ±0.86) ml/kg; week 6:(26.57 ± 1.01 ) ml/kg; week 10:(27.98 ±0.99) ml/kg,F =12.35,P ＞ 0.05 ).In the FST,PCP model rats showed longer still time ( con:(39.32 ± 1.98 ) s ; week 6:(52.39 ± 1.66)s,week 10:(55.56 ± 1.49)s,F=3.99,P＜ 0.05 ).In the RIT,PCP models rats showed less explore time ( (40.31 ± 13.56)s vs (63.90 ± 13.12)s,(43.65 ±12.86 )s vs (65.18 ± 15.12)s,P ＜ 0.05 ) and more escape time ((19.33±2.26) s vs (9.26 ± 1.32) s,(17.79 ±2.99) s vs (9.38 ± 1.36) s,P＜ 0.05).Conclusion Perinatal PCP injection can induce the long-lasting negative-symptoms changes.

The relatively high abundance of geochemical elements such as Nb, Zr, Y and other elements shows serious interferences in the determination of trace silver in geochemical samples by inductively coupled plasma-mass spectrometry ( ICP-MS) . Thus it will lead to large deviation in the determination of geochemical samples without separation and enrichment. The traditional emission spectrum or graphite furnace atomic absorption method is only single-element analysis to the silver and with bad sample representativeness. In this study, load diphenylthiourea ( DPTU) foam selective enrichment was used for the separation of Au and Ag from other interfering elements in geological samples, and thiourea liberation-ICP-MS method was developed for the simultaneous determination of Au and Ag. The samples were first decomposed by 1:1 aqua regia. After addition of 50 mL of water, the samples were adsorbed under oscillation for 30 min at 20℃. The detection limits of the Au and Ag were 0. 02 ng/g and 0. 007μg/g, respectively. The proposed method was successfully applied to the determination of Au and Ag in eight national standard materials.

Metastatic colorectal cancer (mCRC) is a clinical and molecular heterogeneous disease. Currently, for mCRC, extended rat sarcoma (RAS) testing is recommended in routine clinical practice before any treatment. RAS mutational status is significantly associated with the outcome of patients and strongly predictive for anti-EGFR-targeted therapy. However, specific treatments for RAS target are not yet available. Previous studies have shown that direct inhibition of RAS proteins has limited clinical benefits. Recently, a promising drug, AMG-510, which can directly inhibit KRAS G12C has been reported; however, it needs further confirmation. In the past few years, important advances have also been made in approaches designed to indirectly target RAS by inhibiting RAS effectors, multi-target combination strategies and immunotherapy. They are expected to be effective treatments for RAS target. This article summarizes the precision treatment of RAS-mutant mCRC.

Objective:To evaluate clinical efficacy of local treatment for prostate cancer patients with bone metastases at the initial diagnosis.Methods:Clinical data of 211 prostate cancer patients with bone metastases at the initial diagnosis admitted to the First Affiliated Hospital of Soochow University from January 2014 to December 2021 were retrospectively analyzed. All patients were divided into the systemic and combined local treatment groups according to whether they received local treatment or not. Patients in the combined local treatment group were further divided into the prostatectomy and radical radiotherapy groups. According to whether they received radiotherapy, they were divided into the radiotherapy and non-radiotherapy groups. Statistical analysis was performed by SPSS 26.0 statistical software. The differences in the survival of patients among different groups were analyzed and compared by Kaplan-Meier method and log-rank test. The comparison was repeatedly conducted after the propensity score matching. Clinical characteristics and treatment factors of patients were included in Cox's proportional hazard regression model, and their relationship with survival was analyzed.Results:Compared with systemic treatment, local treatment significantly improved the 5-year clinical progression-free survival (CPFS) and 5-year overall survival (OS) ( P=0.049, 0.010). After propensity score matching was performed, patients in the local treatment group outperformed those in the systemic treatment in 5-year biochemical progression-free survival (BPFS) and 5-year OS ( P=0.036, 0.029). There were no statistically significant differences in 5-year BPFS, CPFS and OS between the prostatectomy and radical radiotherapy groups. Radiotherapy improved 5-year BPFS and 5-year OS compared with non-radiotherapy ( P=0.030, 0.020). After propensity score matching was performed, 5-year BPFS and 5-year OS in the radiotherapy group remained significantly higher than those in the non-radiotherapy group ( P=0.046, 0.047). Overall, patients who received radiotherapy were well tolerated and did not experience serious radiation-related adverse events. Radiotherapy improved 5-year OS for patients who were older than 65 years, had bone metastases confined to the pelvis and had a Gleason score of ≤ 8 ( P=0.039, 0.024, 0.036). Conclusions:Local treatment, especially radiotherapy, prolongs BPFS and OS rates in prostate cancer patients with bone metastases at first diagnosis. Radiotherapy appears to be more effective in patients of advanced age, with bone metastases confined to the pelvis and with relatively low Gleason scores.